Skip to main content

Table 1 Clinical characteristics of colon adenocarcinoma patients

From: Prognostic impact of MGMT promoter methylation and MGMT and CD133 expression in colorectal adenocarcinoma

Feature

Classification

n (%)

Sex

Male

80 (65)

 

Female

43 (35)

Age

≥50 years

116 (94.3)

 

<50 years

7 (5.7)

Tumor differentiation grade

Well differentiated

37 (31.6)

 

Moderately differentiated

59 (50.4)

 

Poorly differentiated

21 (17.9)

Tumor stage

I

14 (11.5)

 

II

44 (36.1)

 

III

49 (40.2)

 

IV

15 (12.3)

Radiotherapy treatment

Did not receive radiotherapy

96 (87.3)

 

Received radiotherapy

14 (12.7)

Chemotherapy treatment

Did not receive chemotherapy

47 (38.8)

 

Received chemotherapy

74 (61.2)

Treatment

No chemotherapy or radiotherapy

40 (36.4)

 

Some treatment

70 (63.6)

Treatment response

Response

61 (58.1)

 

No response

44 (41.9)

Last follow-up status

Alive without disease

66 (65.3)

 

Alive with disease

17 (16.8)

 

Disease progression and death

18 (17.8)

  1. Sample size for sex and age (n = 123), for tumor differentiation grade (n = 117), for tumor stage (n = 122), for radiotherapy treatment (n = 110), for chemotherapy treatment (n = 121), for a treatment (n = 110), for treatment response (n = 105) and last follow-up status (n = 101).